ArticleJournal of the American College of Emergency Physicians open2026
Closing the Gap: Expanding Access to Mifepristone for Early Pregnancy Loss Through Operational Innovation.
Article in Journal of the American College of Emergency Physicians open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of early pregnancy loss (EPL) with mifepristone plus misoprostol is the evidence-based standard of care endorsed by the American College of Obstetricians and Gynecologists. This 2-drug regimen demonstrates superior outcomes compared to misoprostol alone or expectant management, including fewer complications, higher success rates, and reduced need for surgical intervention. Though mifepristone use for EPL management is legal in all 50 states, it is vastly underutilized in emergency departments (EDs), which see a substantial percentage of patients with EPL. This is partly due to regulations around prescribing and dispensing it that create logistical barriers, especially in unscheduled care settings. Expanded access to mifepristone in the ED has the potential to reduce disparities in medical care for EPL, especially for patients in rural or underserved areas. Medical therapy for EPL is often mischaracterized as elective abortion, which it is not. This concept paper defines the role of emergency clinicians in prescribing evidence-based medical treatment exclusively for patients with EPL. As restrictive state laws begin to misclassify EPL management as elective abortion care, EDs must be equipped to deliver evidence-based patient care with clarity. Protecting access to guideline-supported medical care for EPL can reduce morbidity and mortality and prevent delays in appropriate care caused by geographic, legal, or institutional barriers. This paper proposes 5 adaptable care models for integrating mifepristone into emergency and urgent care workflows, from on-site prescribing and dispensing to hybrid pathways that incorporate telehealth and follow-up referrals. Each model addresses different levels of institutional readiness, state legal frameworks, and clinical capacity. Implementation guidance includes protocols for eligibility screening, prescribing and dispensing options, and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.